Treatment of Anemia in Patients With Cancer Who Are Not Currently Receiving Chemotherapy or Radiotherapy

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.12 sites in 1 countryFebruary 2004

ConditionsAnemia

Drugsepoetin alfa

Overview

Phase: Phase 3
Intervention: Not specified
Conditions: Anemia
Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Locations: 12
Status: Terminated
Last Updated: 15 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to determine the effectiveness of different doses of epoetin alfa for treating anemia in patients who have cancer; or patients who no longer have any signs of cancer, but remain anemic as a result of their treatment. These patients should not be currently receiving chemotherapy or radiotherapy. A subject's participation in the study will last approximately 6 months. Subjects will receive weekly doses of epoetin alfa or placebo. Their hemoglobin will be tested every week.

Registry

clinicaltrials.gov

Start Date

February 2004

End Date

October 2004

Last Updated

15 years ago

Study Type

Interventional

Sex

All

Investigators

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Eligibility Criteria

Inclusion Criteria

•Body weight \>/=99 lbs
•Anemia results from cancer, chemotherapy, radiotherapy or an association with hormonal therapy or immunotherapy
•Screening hemoglobin level of \</=11.0 g/dL for men or \</=10.0 for women